Circulating biomarkers and outcome from a randomised phase II trial of sunitinib vs everolimus for patients with metastatic renal cell carcinoma Academic Article uri icon

Overview

MeSH Major

  • Biomarkers, Tumor
  • Carcinoma, Renal Cell
  • Everolimus
  • Indoles
  • Kidney Neoplasms
  • Pyrroles

abstract

  • Baseline levels of multiple soluble biomarkers correlated with benefit from everolimus and/or sunitinib, independent of clinical risk factors. A similar PFS1L was observed for both treatments among patients with high CBS score.

publication date

  • March 15, 2016

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4800293

Digital Object Identifier (DOI)

  • 10.1038/bjc.2016.21

PubMed ID

  • 26908330

Additional Document Info

start page

  • 642

end page

  • 9

volume

  • 114

number

  • 6